Laboratory confirmed cases of invasive meningococcal infection (England): April to June 2018

Health Protection Report
Volume 12 Number 35
28 September 2018
Laboratory confirmed cases of invasive meningococcal infection (England): April to June 2018

In England, the national Public Health England (PHE) Meningococcal Reference Unit (MRU) confirmed 175 cases of invasive meningococcal disease (IMD) between April and June 2018 [1]. IMD cases were 19% higher during these three months compared to 147 cases in the equivalent period in 2017 (table 1).

The age distribution of meningococcal capsular groups causing IMD is summarised in table 2, with capsular group B (MenB) accounting for 57% (100/175) of all cases, followed by MenW (n=46, 26%), MenC (n=15, 8.6%), MenY (n=13, 7.4%) and one MenX.

There were 100 MenB cases confirmed between April and June 2018, 25% higher than the equivalent period in 2017 (80 cases). The number of cases confirmed with MenW, MenY and MenC in this quarter were similar to the number confirmed in the second quarter of 2017 (table 1). Whilst confirmed MenC cases remain low, they have increased compared to recent years. There were no reported cases for capsular groups A, Z/E, ungrouped and ungroupable.

Between April and June 2018 MenB was responsible for the majority of IMD cases in children aged less than five years of age (39/59, 66%) but, as expected, contributed to a lower proportion of cases in older age groups (table 2). The introduction of a routine national MenB immunisation programme for infants was announced in June 2015 [2] with immunisation of infants starting from 1 September 2015. Preliminary vaccine coverage estimates for infant MenB immunisation are 95.3% for one dose, 92.9% for two doses and 86.7% for the booster dose by 18 months age (evaluated between January and March 2018) [3]. The two-dose infant MenB schedule has been shown to be highly effective in preventing MenB disease in infants [4].

Of the 46 MenW cases confirmed between April and June 2018, 54% (n=25) were aged 65 years or older followed by infants aged less than 1 year (n=10; 22%) and adults aged 45 to 64 years (n=7, 15%). The increase in MenW cases, which has been previously reported [5,6], led to the introduction of MenACWY conjugate vaccine to the national immunisation programme.
Laboratory confirmed cases of invasive meningococcal infection (England): April to June 2018

Health Protection Report Volume 12 Number 35

in England [7,8]. Targeted catch-up with MenACWY vaccine began in August 2015 at which time it also replaced the existing time-limited MenC ‘freshers’ vaccination programme. MenC vaccine was also directly substituted with MenACWY vaccine in the routine adolescent schools programme (school year 9 or 10) from autumn 2015.

National cumulative MenACWY vaccine coverage to the end of March 2018 was 39.8% for the third GP based catch-up cohort (aged 18-19 years during the 2017/2018 academic year), higher (6.8%) than the second GP based catch-up at the same point in the previous year (33.0%) [9].

Coverage for the first cohorts to be routinely offered MenACWY vaccine in schools from September 2015 and evaluated up to the end August 2017 was 83.6% (Year 9 in 2016/2017), 82.5% (Year 10) 79.0% (Year 11) and 71.4% (Year 12) [10].

All teenage cohorts remain eligible for opportunistic MenACWY vaccination until their 25th birthday and it is important that these teenagers continue to be encouraged to be immunised, particularly if they are entering Higher Educations Institutions. A first assessment of the MenACWY vaccination impact in the 2015 school leaver cohort has been published [11].

The impact of the MenACWY teenage vaccination and the MenB infant programme continue to be monitored.

Table 1. Invasive meningococcal disease in England by capsular group and laboratory testing method: April to June 2018

<table>
<thead>
<tr>
<th>Capsular groups</th>
<th>CULTURE AND PCR 2017</th>
<th>CULTURE AND PCR 2018</th>
<th>CULTURE ONLY 2017</th>
<th>CULTURE ONLY 2018</th>
<th>PCR ONLY 2017</th>
<th>PCR ONLY 2018</th>
<th>Total 2017</th>
<th>Total 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2</td>
<td>2</td>
<td>2</td>
<td>Q2</td>
<td>Q2</td>
<td>Q2</td>
<td>Q2</td>
<td>Q2 - Q2</td>
<td>Q2 - Q2</td>
</tr>
<tr>
<td>B</td>
<td>18</td>
<td>26</td>
<td>16</td>
<td>17</td>
<td>46</td>
<td>57</td>
<td>80</td>
<td>100</td>
</tr>
<tr>
<td>C</td>
<td>1</td>
<td>2</td>
<td>6</td>
<td>7</td>
<td>4</td>
<td>6</td>
<td>11</td>
<td>15</td>
</tr>
<tr>
<td>W</td>
<td>10</td>
<td>5</td>
<td>24</td>
<td>35</td>
<td>9</td>
<td>6</td>
<td>43</td>
<td>46</td>
</tr>
<tr>
<td>Y</td>
<td>2</td>
<td>3</td>
<td>7</td>
<td>7</td>
<td>1</td>
<td>3</td>
<td>10</td>
<td>13</td>
</tr>
<tr>
<td>Other*</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>31</td>
<td>36</td>
<td>53</td>
<td>67</td>
<td>63</td>
<td>72</td>
<td>147</td>
<td>175</td>
</tr>
</tbody>
</table>

~No cases of group A were confirmed during the periods summarised in the table.

* Other includes X, Z/E, ungrouped and ungroupable (ungroupable refers to invasive clinical meningococcal isolates that were non-groupable, while ungrouped cases refers to culture-negative but PCR screen (ctrA) positive and negative for the four genogroups [B, C, W and Y] routinely tested for).
Table 2. Invasive meningococcal disease in England by capsular group and age group at diagnosis: April – June 2018

<table>
<thead>
<tr>
<th>Age groups</th>
<th>Capsular Group~</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th>Total</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B</td>
<td>C</td>
<td>W</td>
<td>Y</td>
<td>Other*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1 year</td>
<td>20</td>
<td>5</td>
<td>10</td>
<td>1</td>
<td>0</td>
<td>36</td>
<td>20.6</td>
</tr>
<tr>
<td>1-4 years</td>
<td>19</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>23</td>
<td>13.1</td>
</tr>
<tr>
<td>5-9 years</td>
<td>14</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>15</td>
<td>8.6</td>
</tr>
<tr>
<td>10-14 years</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>2.3</td>
</tr>
<tr>
<td>15-19 years</td>
<td>13</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>13</td>
<td>7.4</td>
</tr>
<tr>
<td>20-24 years</td>
<td>7</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>9</td>
<td>5.1</td>
</tr>
<tr>
<td>25-44 years</td>
<td>6</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>11</td>
<td>6.3</td>
</tr>
<tr>
<td>45-64 years</td>
<td>10</td>
<td>0</td>
<td>7</td>
<td>2</td>
<td>0</td>
<td>19</td>
<td>10.9</td>
</tr>
<tr>
<td>&gt;=65 years</td>
<td>8</td>
<td>6</td>
<td>25</td>
<td>5</td>
<td>1</td>
<td>45</td>
<td>25.7</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>15</td>
<td>46</td>
<td>13</td>
<td>1</td>
<td>175</td>
<td></td>
</tr>
</tbody>
</table>

~No cases of groups A, Z/E, ungrouped and ungroupable (ungroupable refers to invasive clinical meningococcal isolates that were non-groupable, while ungrouped cases refers to culture-negative but PCR screen (ctrA) positive and negative for the four genogroups [B, C, W and Y] routinely tested for) were confirmed during the periods summarised in the table.

* Other includes group X.
References

1. Data source: PHE Meningococcal Reference Unit, Manchester.
8. PHE website. Meningococcal ACWY (MenACWY) vaccination programme.
9. PHE (2018). Vaccine coverage for the GP based catch-up meningococcal ACWY (MenACWY) immunisation programme in England to the end of March 2018. HPR 12(18), 25 May 2018
About Public Health England

Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health, and are a distinct delivery organisation with operational autonomy to advise and support government, local authorities and the NHS in a professionally independent manner.

About Health Protection Report

Health Protection Report is a national public health bulletin for England and Wales, published by Public Health England. It is PHE’s principal channel for the dissemination of laboratory data relating to pathogens and infections/communicable diseases of public health significance and of reports on outbreaks, incidents and ongoing investigations.

Public Health England, Wellington House, 133-155 Waterloo Road, London SE1 8UG
Tel: 020 7654 8000  www.gov.uk/phe
Twitter: @PHE_uk  Facebook: www.facebook.com/PublicHealthEngland
Queries relating to this document should be directed to:
Immunisation, Hepatitis and Blood Safety Department,
National Infection Service, PHE Colindale,
61 Colindale Avenue, London NW9 5EQ.
immunisation@phe.gov.uk

© Crown copyright 2018
You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL or email psi@nationalarchives.gsi.gov.uk. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published September 2018

PHE supports the UN PHE Sustainable Development Goals

Corporate member of Plain English Campaign
Committed to clearer communication

SUSTAINABLE DEVELOPMENT GOALS